皮肤冠状动脉干预中的药物涂层气球:超越证据
Nagi Azzi1, Randa N Tabbah1,2,3
1Cardiology, Lebanese American University School of Medicine, Beirut, LBN.
Cureus
|December 5, 2024
概括
药物涂层气球 (DCB) 为药物释放支架 (DES) 提供了一个"不留下任何东西"的替代方案,在急性冠状动脉综合征中显示了相似的结果和潜在的益处. 进一步的研究可能会确定DCB作为主要的干预心脏病学方法.
科学领域:
- 干预心脏病学 干预心脏病学
- 心血管器械 心血管器械
背景情况:
- 药物涂层气球 (DCB) 是一种无金属的替代品,可以替代药物排泄支架 (DES).
- DCBs避免了长期的并发症,如血管损伤和支架血栓形成.
- 从历史上看,用于静脉静脉阻滞或小血管,DCBs对急性冠状动脉综合征 (ACS) 有希望.
研究的目的:
- 评估DCBs作为DESs的替代品的有效性和安全性.
- 探索DCB不断扩大的临床应用,特别是在ACS中.
- 评估与DES相比DCB治疗的长期结果.
主要方法:
- 对DCB与DES治疗的比较试验.
- 对DCB在各种急性冠状动脉综合征 (ACS) 的使用进行分析,包括STEMI和NSTEMI.
- 对DCB应用新出现的技术指南和最佳实践的审查.
主要成果:
- 稳定型银行表现出与DES相似的长期结果.
- 一些研究表明,在ACS患者中,DCBs降低了二次终点 (心脏死亡,心肌梗塞).
- 在各种临床场景中显示出有希望的安全性和有效性,包括组合疗法.
结论:
- 对某些患者来说,DCB是DES的可行替代品.
- 在干预性心脏病学中,DCB显示出更广泛应用的潜力.
- 进一步的研究将澄清长期结果,并巩固稳定性银行 (DCB) 的作用.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
141
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
468
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
468
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
455
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
455
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K


